Seres Therapeutics (MCRB) Preclinical 109 is Underway - JMP Securities
Tweet Send to a Friend
JMP Securities analyst Gobind Singh reiterated a Market Perform rating on Seres Therapeutics (NASDAQ: MCRB) after a management presentation confirmed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


